Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
DURHAM, N.C., Sept. 06, 2016 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H, Chief Executive Officer of Chimerix, will present at the Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016 at 4:15 p.m. ET at the Grand Hyatt Hotel in New York City.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at http://ir.chimerix.com/events.cfm, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel antivirals in areas of high unmet medical need. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates, including CMX669. Chimerix is also advancing a clinical candidate for norovirus infection, CMX521. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT: Investor Relations: [email protected] or Jesse Baumgartner Stern Investor Relations [email protected] 212-362-1200 Media: Becky Vonsiatsky W2O Group [email protected] 413-478-2003
